Contra-indicated in patients with severe renal impairment, moderate or severe hepatic impairment, a history of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions.
- TRADE NAME: Zelnorm (Novartis)
- INDICATIONS: Irritable bowel syndrome
- CLASS: 5-HT4 agonist, Serotonin type 4 receptor agonist
- HALF-LIFE: 11±5 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
